OSU-2S

Research use only, not for human use.

A non-immunosuppressive FTY720 analogue, PKCδ activator with higher antiproliferative potency.

A non-immunosuppressive FTY720 analogue, PKCδ activator with higher antiproliferative potency with IC50 of 2.4, 2.4, and 3.5 uM in Huh7, Hep3B, and PLC5 cells, respectively; exhibited higher in vitro antiproliferative efficacy relative to FTY720 against HCC cells without cytotoxicity in normal hepatocytes, although devoid of S1P1 receptor activity; induces caspase-dependent apoptosis through ROS-dependent PKCδ activation in HCC tumor cells.

Cell Proliferation AssayCell Line:Hep3B, Huh7, PLC-5, HepG2 cells Concentration:0-10 μM Incubation Time:48 h Result:Showed anti-proliferative effects with IC50s of 2.53, 2.41, 3.96, 1.84 μM for Hep3B, Huh7, PLC-5, HepG2 cells, respectively.Western Blot Analysis Cell Line:Hep3B cells Concentration:1.25, 2.5 μM combinated with sorafenib (2.5, 5 μM)Incubation Time:48 h Result:Decreased the expression of ERK1/2 phosphorylation, increased the expression of PKCδ (38 kDa) when sorafenib/OSU-2S combination.

Animal Model:CD2F1 mice (Hep3B tumor xenograft models)Dosage:5, 10 mg/kg Administration:I.p.; once daily for 42 days Result:Exhibited a higher tumor-suppressive potency, achieving 80% reduction in bioluminescence at the end of treatment.

OSU 2S

Angiogenesis

PKC

PKC

——

——

1351056-65-9

335.532

C21H37NO2

>98% (HPLC)

——

CCC[C@@](CCC1=CC=C(OCCCCCC(C)C)C=C1)(N)CO.[H]Cl

(S)-2-amino-2-(4-[(6-methylheptyl)-oxy]phenethyl)pentan-1-ol

(-20℃)

With Ice Pack

≥ 2 years